[144] Taylor Morrison Home Corporation SEC Filing

Rhea-AI Filing Summary

Amendment No. 3 to Schedule 13G: FMR LLC and Abigail P. Johnson report a passive ownership position in Viking Therapeutics (VKTX) as of 30 June 2025.

• Shares beneficially owned: 9,767,897.52 common shares
• Ownership percentage: 8.7 % of outstanding stock
• Sole voting power: 9,688,737.12 shares; shared voting power: 0
• Sole dispositive power: 9,767,897.52 shares; shared dispositive power: 0

The filing is made under Rule 13d-1(b); FMR LLC is classified as a parent holding company/control person (HC). The certification states the stake was acquired and is held in the ordinary course of business and not to influence control of VKTX. Signatures were executed by Richard Bourgelas under a power of attorney on 5 Aug 2025.

Positive

• FMR LLC reports a sizeable 8.7 % passive stake (9.77 M shares) in VKTX, adding a high-profile institutional holder to the share register.

Negative

• None.

Insights

Securities Analyst

TL;DR: Disclosure shows Fidelity unit holds 8.7 % of VKTX; passive, no control intent—neutral for valuation but highlights rising institutional interest.

FMR LLC’s 9.8 M-share position confirms substantial institutional ownership in VKTX. Because the Schedule 13G is filed under Rule 13d-1(b) (passive), no activism or control effort is implied. The stake’s size (near 9 %) can improve liquidity and visibility, yet it does not directly change the company’s fundamentals. Investors may view Fidelity’s involvement as a vote of confidence, but there are no new financial metrics, guidance, or transactions disclosed. Overall market impact should be modest and driven mainly by perception rather than cash-flow effects.

Corporate Governance Expert

TL;DR: Filing signals significant but non-activist holding; governance impact minimal unless stake crosses 10 %.

Because FMR LLC remains below the 10 % threshold, it avoids Schedule 13D obligations and related influence on board matters. The certification explicitly disclaims any intent to influence control, reducing governance risk for existing management. Should the position grow, monitoring for a 13D conversion would be prudent. At present, the disclosure primarily enhances transparency and meets SEC requirements without altering Viking Therapeutics’ governance landscape.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	9754	636158.60	98843205	08/06/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/06/2025	Option Granted - 02/10/2020	Issuer			1501	08/06/2025	Cash
Common	08/06/2025	Option Granted - 02/16/2021	Issuer			7125	08/06/2025	Cash
Common	08/06/2025	Option Granted - 05/04/2021	Issuer			1128	08/06/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Viking Therapeutics (VKTX) shares does FMR LLC own?

FMR LLC reports beneficial ownership of 9,767,897.52 common shares.

What percentage of VKTX’s outstanding stock does FMR LLC control?

The filing states an ownership of 8.7 % of the common shares.

Is FMR LLC seeking control of Viking Therapeutics?

No. The Schedule 13G is filed under Rule 13d-1(b) and the certification affirms the stake is passive and held in the ordinary course of business.

What voting power does FMR LLC have in VKTX?

FMR LLC lists sole voting power over 9,688,737.12 shares and no shared voting power.

When was the ownership stake effective and when was the filing signed?

The stake is reported as of 30 June 2025; signatures were executed on 5 August 2025.